DBV Technologies | DBVT - 普通股股本



金融业
股票价格
USD
资产
USD 233.72M
现金及等价物
USD 194.17M
流动资产
USD 212.94M
流动负债
USD 58.03M
债务
USD 8.59M
股息收益率
USD 0
EBIT
USD -34.28M
EBITDA
USD -33.49M
员工
USD 104
EPS每股收益
USD -0.24
股本和储备
USD 168.77M
销售毛利
USD 2.77M
债务利息支出
USD 461K
利息收入
USD -0.32
贷款资金
USD 0
市值
USD 727.7M
净收入
USD -33.16M
营业费用
USD 37.05M
营业利润
USD -34.28M
普通股股本
USD 136.82M
税前利润
USD -33.16M
销售收入
USD 2.77M
销售和管理费用
USD 3.63M
贸易债权人
USD 39.82M
应收帐款人
USD 15.97M


普通股股本 更改 日
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Amarin USD 20.81M 13K 2025-12
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
DBV Technologies USD 136.82M 51.98K 2025-09
Esperion Therapeutics USD 245.22M 39.79M 2025-12
Galectin Therapeutics USD 61K 0 2023-12
Halozyme Therapeutics USD 118.52M 741K 2026-03
Incyte USD 199.95M 1.49M 2026-03
Insmed USD 216.52M 2.27M 2026-03
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
Neurocrine Biosciences USD 100.6M 500K 2026-03
PTC Therapeutics USD 81.47M 1.54M 2025-12
Sarepta Therapeutics USD 105.57M 607K 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
United Therapeutics USD 42.16M 1.49M 2026-03